Hepatocellular Carcinoma, Cancer
ADAGAdagene IncCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 update for Muzastotug (ADG126) (Masked Anti-CTLA-4) in Hepatocellular Carcinoma, Cancer. The expected timing is based on the latest available company guidance and may change.
03/17/26:- AACR 2026 presents Morpheus Liver Phase 1b/2 HCC results for muzastotug combination arm on April 20, 2026. 04/17/26:- MORPHEUS-Liver Ph1b/2 triplet ORR 66.7% vs 32.5%; safety comparable. 08/12/26:- Reiterated MORPHEUS-Liver Ph1b/2 triplet data showed 66.7% response rate and comparable safety.
Verification
Confirm timing and program details against the company announcement or filing.